Showing results (421-430 of 450) with videos related to

Sort By:
Pageof 45
Journal for Immunotherapy of Cancer|June 9, 2023
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Bonnie Yates, Alina Dulau-Florea, et al.
Nature Communications|July 28, 2016
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticityElad Jacoby, Sang M Nguyen, Thomas J Fountaine, et al.
Journal for Immunotherapy of Cancer|November 28, 2020
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemiaGeorge Mo, Hao-Wei Wang, Aimee C Talleur, et al.
Scientific Reports|June 15, 2023
Visiting nature is associated with lower socioeconomic inequalities in well-being in WalesJoanne K Garrett, Francis M Rowney, Mathew P White, et al.
The Journal of Clinical Investigation|January 30, 2019
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapyTori N Yamamoto, Ping-Hsien Lee, Suman K Vodnala, et al.
Med (New York, N.Y.)|March 29, 2024
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trialEhab Bakbak, Aishwarya Krishnaraj, Deepak L Bhatt, et al.
Lancet (London, England)|October 17, 2014
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialDaniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, et al.
Blood Advances|December 18, 2025
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemiaAlexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, et al.
Molecular Cancer Therapeutics|February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAlka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
Pageof 45